New Imaging Biomarkers Predictive of MA Progression (MR7T-PRADA)
Alzheimer Disease, Magnetic Resonance Spectroscopy, Ultra High Field 7T
About this trial
This is an interventional other trial for Alzheimer Disease
Eligibility Criteria
Inclusion Criteria: French-speaking patients aged 60 to 90 years, Patient in the context of Alzheimer's disease * for which imaging after MRI is prescribed as part of the usual diagnostic process, *Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR/RI defined by a sum of LR < 17/48 and sum of RT < 40/48 +/- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +/- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery). MOCA cognitive scale score ≥20, Written informed consent after the patient has been informed, Progressive decline for at least 6 months. Exclusion Criteria: --Partially or completely illiterate patient unable to read and write, Patient with an absolute contraindication to 7T MRI Severe psychiatric pathology not balanced, Non-degenerative neurological disease (stroke, multiple sclerosis ...), Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score > 3)
Sites / Locations
- Chu PoitiersRecruiting
Arms of the Study
Arm 1
Experimental
patient with early onset Alzheimer's disease